Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (CUP)
This treatment has been approved for sale to the public.
Genzyme, a Sanofi Company
First Posted: February 15, 2006
Last Update Posted: February 11, 2014
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This treatment has been approved for sale to the public.|
|Study Completion Date:||No date given|
|Primary Completion Date:||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Deol A, Abrams J, Masood A, Al-Kadhimi Z, Abidi MH, Ayash L, Lum LG, Ratanatharathorn V, Uberti JP. Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplant. 2013 Aug;48(8):1112-6. doi: 10.1038/bmt.2013.10. Epub 2013 Mar 11.